非小细胞肺癌组织中C-erbB-2蛋白的表达对预后和术后化疗疗效的影响

目的探讨C-erbB-2蛋白表达对非小细胞肺癌预后和术后化疗效果的影响。方法应用免疫组织化学LSAB方法检测18例根治术后行含铂类辅助化疗的Ⅲa期非小细胞肺癌(术后化疗组)石蜡切片中C-erbB-2蛋白的表达情况,选同期单独手术的15例Ⅲa期患者(单纯手术组)作为对照,应用Kaplan-Meier法和多变量Cox比例风险模型进行分析。结果(1)C-erbB-2蛋白表达与年龄、T分期之间未发现相关性(P>0．05),但与组织学分级呈负相关(P<0．05)。(2)C-erbB-2蛋白表达阳性率为45．45％,在单纯手术组、术后化疗组中阳性者和阴性者生存率差异具有统计学意义(P<0．05)。(3)多因素Cox风险模型分析,提示C-erbB-2蛋白、p53是影响术后化疗效果的独立指标。结论C-erbB-2蛋白表达是预后较差的指标之一,其表达阳性者较阴性者对化疗不敏感,如何提高术后化疗疗效尚需深入研究。

Effects of C-erbB-2 protein expression on prognosis and adjuvant chemotherapy in non-small cell lung cancer

Objective To determine the effecls of C-erbB-2 protein expression on prognosis and adjuvant chemotherapy in non-small cell lung carcinoma (NSCLC). Methods Expression of C-erbB-2 protein in 18 patients with NSCLC who received radical surgery and cisplatin-based chemotherapy after operation were detected (surgery plus chemotherapy group )by LSAB immunohistochemical method in contrast with 15 patients with NSCLC received surgery alone (single surgery group). Kaplan-Meier method and Cox proportional hazard model were used to analyze. Results ( 1 )The expression of C-erbB-2 protein had no relationship with age and T stage (P>0.05). but had negative relationship with histologicalgrade(P<0.05). (2 )The positive rate of C-erbB-2 protein was 45.45%, there was significant difference between patients with positive and negative C-erbB-2 protein expression in single surgery and surgery plus chemotherapy group (P < 0.05).(3)Cox's model showed that C-erbB-2 protein and p53 had separately impacts on prognosis in surgery plus chemotherapy group. Conclusions Overexpression of C-erbB-2 protein suggests poor prognosis, overexpression of C-erbB-2 protein has tendency resist to chemotherapy in NSCLC.